Healthcare Equipment and Supplies
Company Overview of Provista Diagnostics, Inc.
Provista Diagnostics, Inc. develops and commercializes blood-based diagnostic tests for early oncology-related disease state recognition and detection. It focuses on women's cancers such as breast and ovarian cancer. The company offers dtectDx Breast, a blood test for detection of early breast cancer development. Additionally, it provides contract laboratory services to the molecular diagnostic and pharmaceutical industries. Provista Diagnostics, Inc. was founded in 2007 and is based in Scottsdale, Arizona.
17301 North Perimeter Drive
Scottsdale, AZ 85255
Founded in 2007
Key Executives for Provista Diagnostics, Inc.
Chief Executive Officer and President
Clinical Laboratory Director
Compensation as of Fiscal Year 2014.
Provista Diagnostics, Inc. Key Developments
Provista Diagnostics Completes Enrollment of its 001 Prospective Study of Protein-Based Biomarker Blood Test to Aid in Detection of Breast Cancer
Jul 15 14
Provista Diagnostics, Inc. announced that the final patient has been enrolled in a prospective, blinded, randomized study of Provista's proteomic breast cancer detection test. The 001 study is designed to utilize Provista's proprietary blood test in conjunction with standard of care to help assess the presence of breast cancer in patients with suspicious breast lesions. The trial enrolled 351 women, 25 to 49 years of age who were classified under the Breast Imaging-Reporting and Data System (BI-RADS(R)) Assessment Category 3 or 4. BI-RAD 3 patients are defined as women with lesions that are probably benign and Assessment Category 4, defined as suspicious for malignancy. Women under the age of 50 were specifically enrolled due to the limitations of current detection modalities for women in this age group. Additionally, cancers found in women under the age of 50 have been shown to be more aggressive. Provista's test is used in conjunction with a BI-RADS 3 or 4 classification, which is based on suspicious anatomical changes, by providing further evidence as to the biochemical signature of the individual patient. By providing both biochemical and anatomic information to physicians, the goal is to precisely inform whether the patient should undergo biopsy, further imaging studies or a 6-month follow-up.
Provista Diagnostics, Inc. Appoints Rao V. Mulpuri as Chief Operating Officer
Jul 7 14
Provista Diagnostics, Inc. announced the appointment of Rao V. Mulpuri, PhD, MBA, as Chief Operating Officer (COO). In this role, Dr. Mulpuri will be responsible for leading and managing all aspects of the company's operations, including integration of the scientific and business functions, as well as quality and regulatory oversight to support the launch of Provista's pipeline of products. Most recently, Dr. Mulpuri served as Vice President of Laboratory Operations for AssureRx Health, Inc.
Provista Diagnostics, Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 02:30 PM
Jun 13 14
Provista Diagnostics, Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 02:30 PM. Venue: New York Palace Hotel – 455 Madison Avenue, New York, NY 10022, United States. Speakers: David E. Reese, Chief Executive Officer and President.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 8, 2014